Not all plaque analysis software are the same

Cleerly’s AI-enabled CCTA solution provides comprehensive, accurate, and trackable insights to personalize heart attack prevention

Request a Demo

cleerly-plaque-why-it-matters

ACC/AHA guidelines highlight the importance of plaque, particularly high-risk plaque, as a driver of major adverse cardiovascular events (MACE)1

  • Plaque silently builds up over decades until MACE
  • Determining the amount and type of atherosclerosis (plaque) present may enable earlier diagnosis and facilitate precision treatment2,3

Assessing atherosclerosis is challenging due to limitations of current image processing4

cleerly-plaque-assessing
 

Cleerly advanced coronary plaque analysis

Predicting cardiovascular risk with AI precision


Vessel-by-vessel detail
Precision phenotyping for each artery and branch with stenosis quantification and vascular remodeling scores

Comprehensive plaque assessment
At-a-glance view of characterized plaque volume by coronary region

Stenosis scoring
Clear and concise summary of identified stenoses by severity

Supports next-gen hardware
Advanced segmentation on photon-counting CT

cleerly-labs-overview

The Cleerly difference

Accurately depicting atherosclerosis, even high-risk plaque3,5-10

 

other-methods-iii-readers

Level 3 Expert Readers

Cleerly was superior compared with Level 3 Expert Readers in determining stenosis severity, plaque volume, and composition.7

other-methods-iii-readers

Quantitative Coronary Angiography (QCA)

Cleerly demonstrated high diagnostic performance for determining stenosis severity.9

other-methods-mpi

Myocardial Perfusion Imaging (MPI)

Cleerly demonstrated higher diagnostic performance than MPI for detecting obstructive coronary artery disease.11

other-methods-ivus

Intravascular Ultrasound (IVUS)

Cleerly demonstrated high agreement with IVUS for absolute measures of coronary lumen size to determine accurate stenoses measurements.10

other-methods-nirs

Near-field Infrared Spectroscopy (NIRS)

Cleerly demonstrated high agreement with NIRS for the identification of lipid-rich plaques.10

Backed by clinical evidence

See the demonstrated clinical evidence of the Cleerly AI platform

predict-mace

Adding Cleerly increases the likelihood to predict future MACE12

N=536 patients followed for 2, 5, and 10 years based upon QCT and atherosclerosis

physician-confidence

3-4x increase in physician confidence3

CERTAIN Trial: Change in confidence with AI-QCT (N=775)3

Fewer false positive stenoses13,14

PROMISE Trial: Cleerly downgraded 41% of significant stenosis reads (N=4347)

Earlier plaque detection15

In the CONSERVE trial
(N=747)

In a retrospective analysis of the PARADIGM trial
(N=99)

cleerly_plaque_53-percent

LESS SIGNIFICANT STENOSES THAN CLINICAL READERS, LEADING TO LESS UNNECESSARY DOWNSTREAM TESTING

cleerly_plaque_87-percent

OF PLAQUES WERE PRESENT AT THE SAME LOCATION AS SMALL PLAQUES ON BASELINE CCTA

Request your Cleerly demo

Contact us for a one-on-one software demonstration with a Cleerly expert to see how bringing Cleerly’s AI‑driven CCTA analysis to your organization can empower you to provide personalized treatment decisions for your patients.

Request a Demo